Shanghai Haohai Biological Technology Co. Ltd (F:5HB) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Haohai Biological Technology Co. Ltd (5HB)
Shanghai Haohai Biological Technology Co. Ltd (F:5HB) has a market capitalization of $74.10 Million (€63.38 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #20308 globally and #1851 in its home market, demonstrating a 1.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Haohai Biological Technology Co. Ltd's stock price €1.77 by its total outstanding shares 35807240 (35.81 Million). See reinvestment intensity of Shanghai Haohai Biological Technology Co to understand how much of operating cash flow is reinvested back into capital assets.
Shanghai Haohai Biological Technology Co. Ltd Market Cap History: 2015 to 2026
Shanghai Haohai Biological Technology Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $33.76 Million to $74.10 Million (8.72% CAGR).
Shanghai Haohai Biological Technology Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Haohai Biological Technology Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.32x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $30.21 Million | $851.16 Million | $305.05 Million | 0.04x | 0.10x |
| 2017 | $30.49 Million | $1.34 Billion | $372.42 Million | 0.02x | 0.08x |
| 2018 | $35.85 Million | $1.55 Billion | $414.54 Million | 0.02x | 0.09x |
| 2019 | $48.97 Million | $1.60 Billion | $370.78 Million | 0.03x | 0.13x |
| 2020 | $56.06 Million | $1.32 Billion | $230.07 Million | 0.04x | 0.24x |
| 2021 | $69.36 Million | $1.75 Billion | $352.23 Million | 0.04x | 0.20x |
| 2022 | $67.63 Million | $2.10 Billion | $180.47 Million | 0.03x | 0.37x |
| 2023 | $80.43 Million | $2.63 Billion | $416.12 Million | 0.03x | 0.19x |
| 2024 | $135.63 Million | $2.68 Billion | $420.45 Million | 0.05x | 0.32x |
Competitor Companies of 5HB by Market Capitalization
Companies near Shanghai Haohai Biological Technology Co. Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Shanghai Haohai Biological Technology Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Shanghai Haohai Biological Technology Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Haohai Biological Technology Co. Ltd's market cap moved from $33.76 Million to $ 74.10 Million, with a yearly change of 8.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €74.10 Million | -32.44% |
| 2025 | €109.68 Million | -19.14% |
| 2024 | €135.63 Million | +68.63% |
| 2023 | €80.43 Million | +18.94% |
| 2022 | €67.63 Million | -2.49% |
| 2021 | €69.36 Million | +23.72% |
| 2020 | €56.06 Million | +14.49% |
| 2019 | €48.97 Million | +36.58% |
| 2018 | €35.85 Million | +17.59% |
| 2017 | €30.49 Million | +0.93% |
| 2016 | €30.21 Million | -10.53% |
| 2015 | €33.76 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Shanghai Haohai Biological Technology Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $74.10 Million USD |
| MoneyControl | $74.10 Million USD |
| MarketWatch | $74.10 Million USD |
| marketcap.company | $74.10 Million USD |
| Reuters | $74.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more